Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome

Eldad J. Dann, Ron Epelbaum, Ada Tamir et al.|Blood|2006

Cited by 124